Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
McKesson
Dow

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Fedovapagon

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Fedovapagon: Sponsors, patents, clinical trial progress

Fedovapagon is an investigational drug.

There have been 4 clinical trials for Fedovapagon. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2016.

The most common disease conditions in clinical trials are Nocturia, Prostatic Hyperplasia, and Hyperplasia. The leading clinical trial sponsors are Vantia Ltd and [disabled in preview].

There are six US patents protecting this investigational drug and one hundred and sixteen international patents.

Recent Clinical Trials for Fedovapagon
TitleSponsorPhase
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)Vantia LtdPhase 2/Phase 3
A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC IntervalVantia LtdPhase 1
Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of FedovapagonVantia LtdPhase 1

See all Fedovapagon clinical trials

Clinical Trial Summary for Fedovapagon

Top disease conditions for Fedovapagon
Top clinical trial sponsors for Fedovapagon

See all Fedovapagon clinical trials

US Patents for Fedovapagon

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fedovapagon   Start Trial Condensed azepines as vasopressin agonists Ferring BV (Hoofddorp, NL)   Start Trial
Fedovapagon   Start Trial Fused azepine derivatives and their use as antidiuretic agents Ferring BV (Hoofddorp, NL)   Start Trial
Fedovapagon   Start Trial Condensed azepines as vasopressin agonists Vantia Limited (GB)   Start Trial
Fedovapagon   Start Trial Polymorph of 1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamo- yl)-L-proline-N,N-dimethylamide Vantia Limited (Southampton, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fedovapagon

Drugname Country Document Number Estimated Expiration Related US Patent
Fedovapagon Argentina 035327 2020-01-05   Start Trial
Fedovapagon Austria 366730 2020-01-05   Start Trial
Fedovapagon Australia 2384601 2020-01-05   Start Trial
Fedovapagon Australia 777538 2020-01-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Harvard Business School
McKesson
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.